Peter D Sasieni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7903744/publications.pdf Version: 2024-02-01



DETED D SASIENI

#	Article	IF	CITATIONS
1	A case–control study to evaluate the impact of the breast screening programme on breast cancer incidence in England. Cancer Medicine, 2023, 12, 1878-1887.	2.8	8
2	Non-speculum sampling approaches for cervical screening in older women: randomised controlled trial. British Journal of General Practice, 2022, 72, e26-e33.	1.4	14
3	Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot. Lancet Oncology, The, 2022, 23, 270-278.	10.7	28
4	Modeling Multicancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 3-4.	2.5	0
5	Alternative analysis of the data from a HPV vaccine study in India. Lancet Oncology, The, 2022, 23, e9.	10.7	3
6	Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial. BMJ Open, 2022, 12, e054258.	1.9	6
7	Self-sampling for cervical screening offered at the point of invitation: A cross-sectional study of preferences in England. Journal of Medical Screening, 2022, 29, 194-202.	2.3	11
8	Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study. Cancer Medicine, 2022, 11, 1160-1171.	2.8	3
9	Benefit of biennial faecal occult blood screening on colorectal cancer in England: A population-based case-control study. Journal of the National Cancer Institute, 2022, , .	6.3	1
10	Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine, 2022, 28, 958-964.	30.7	19
11	HPV vaccination and cervical cancer screening – Authors' reply. Lancet, The, 2022, 399, 1940.	13.7	1
12	Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study. Lancet Public Health, The, 2022, 7, e537-e548.	10.0	38
13	Cervical cell lift: A novel triage method for the spatial mapping and grading of precancerous cervical lesions. EBioMedicine, 2022, 82, 104157.	6.1	4
14	Management strategies for the colonoscopic surveillance of people with Lynch syndrome during the COVID-19 pandemic. Gut, 2021, 70, 624-626.	12.1	7
15	Comparison of immediate colposcopy, repeat conventional cytology and highâ€risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The <scp>ASCUSâ€COL</scp> trial. International lournal of Cancer, 2021, 148, 1394-1407.	5.1	5
16	Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1226-1235.	2.3	6
17	A case-control study to evaluate the impact of the breast screening programme on mortality in England. British Journal of Cancer, 2021, 124, 736-743.	6.4	14
18	Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study. British Journal of Cancer, 2021, 124, 1026-1032.	6.4	12

#	Article	IF	CITATIONS
19	Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses. British Journal of Cancer, 2021, 124, 1361-1365.	6.4	43
20	Multizonal anogenital neoplasia in women: a cohort analysis. BMC Cancer, 2021, 21, 232.	2.6	6
21	Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. EClinicalMedicine, 2021, 37, 100969.	7.1	5
22	Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: A population-based case-control study. Preventive Medicine, 2021, 149, 106625.	3.4	8
23	Awareness of the link between human papillomavirus and oral cancer in UK university students. Preventive Medicine, 2021, 150, 106660.	3.4	8
24	Exposure Definition in Case–Control Studies of Cervical Cancer Screening: A Systematic Literature Review. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2154-2166.	2.5	3
25	Reply to †Intraoperative radiotherapy for breast cancer: powerful evidence to change practice'. Nature Reviews Clinical Oncology, 2021, 18, 188-189.	27.6	7
26	The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet, The, 2021, 398, 2084-2092.	13.7	305
27	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. International Journal of Cancer, 2020, 146, 617-626.	5.1	5
28	Costâ€effectiveness of e igarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction, 2020, 115, 507-517.	3.3	35
29	Impact of screening on cervical cancer incidence: A populationâ€based case–control study in the United States. International Journal of Cancer, 2020, 147, 887-896.	5.1	20
30	Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach. The Lancet Digital Health, 2020, 2, e37-e48.	12.3	19
31	Flexible use of flexible sigmoidoscopy. Journal of Medical Screening, 2020, 27, 57-58.	2.3	0
32	Cancer Screening, Surrogates of Survival, and the Soma. Cancer Cell, 2020, 38, 433-437.	16.8	14
33	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Communications, 2020, 11, 4841.	12.8	129
34	A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. Gynecologic Oncology, 2020, 159, 344-353.	1.4	9
35	Intraoperative radiotherapy for early breast cancer — insufficient evidence to change practice. Nature Reviews Clinical Oncology, 2020, 17, 723-724.	27.6	12
36	Evidence of HPV vaccination efficacy comes from more than clinical trials. Vaccine, 2020, 38, 5569-5571.	3.8	0

#	Article	IF	CITATIONS
37	Lectins in Cervical Screening. Cancers, 2020, 12, 1928.	3.7	1
38	Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet, The, 2020, 396, 333-344.	13.7	143
39	Survival from Cervical Cancer Diagnosed Aged 20–29 Years by Age at First Invitation to Screening in England: Population-Based Study. Cancers, 2020, 12, 2079.	3.7	4
40	Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncology, The, 2020, 21, 1165-1172.	10.7	110
41	Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study. Journal of Medical Screening, 2020, 28, 096914132095344.	2.3	2
42	Mammography screening for breast cancer—the UK Age trial – Authors' reply. Lancet Oncology, The, 2020, 21, e510.	10.7	2
43	Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study. Cancer Epidemiology, 2020, 67, 101759.	1.9	7
44	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). British Journal of Cancer, 2020, 123, 510-517.	6.4	74
45	Errors in determination of net survival: cause-specific and relative survival settings. British Journal of Cancer, 2020, 122, 1094-1101.	6.4	19
46	Population-level impact of human papillomavirus vaccination. Lancet, The, 2020, 395, 412.	13.7	0
47	High-dose oral vitamin D supplementation and mortality in people aged 65–84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation. Health Technology Assessment, 2020, 24, 1-54.	2.8	16
48	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. Health Technology Assessment, 2020, 24, 1-24.	2.8	23
49	Equality and equity in medical screening: what is fair?. The Lancet Gastroenterology and Hepatology, 2019, 4, 578-580.	8.1	5
50	A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method. BMC Cancer, 2019, 19, 632.	2.6	21
51	Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP) Tj ETQ	q1 1.0.78 10.7	4314 rgBT /O
52	Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol. Lancet Respiratory Medicine,the, 2019, 7, 655-656.	10.7	18
53	Impact of screening on cervical cancer incidence in England: a time trend analysis. BMJ Open, 2019, 9, e026292.	1.9	25
54	A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. New England Journal of Medicine, 2019, 380, 629-637.	27.0	1,050

#	Article	IF	CITATIONS
55	Is a delay in the introduction of human papillomavirus-based cervical screening affordable?. Journal of Medical Screening, 2019, 26, 44-49.	2.3	9
56	Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?. Lung Cancer, 2019, 130, 208-215.	2.0	16
57	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	2.4	153
58	Cancer elimination thresholds: one size does not fit all. Lancet Public Health, The, 2019, 4, e86.	10.0	1
59	Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. Lancet Oncology, The, 2019, 20, e637-e644.	10.7	76
60	Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. Journal of Clinical Microbiology, 2019, 57, .	3.9	26
61	Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. Journal of Internal Medicine, 2019, 285, 436-445.	6.0	20
62	E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT. Health Technology Assessment, 2019, 23, 1-82.	2.8	43
63	Acceptability of non-speculum clinician sampling for cervical screening in older women: A qualitative study. Journal of Medical Screening, 2018, 25, 205-210.	2.3	16
64	Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037. British Journal of Cancer, 2018, 118, 1391-1398.	6.4	23
65	ls the recent increase in cervical cancer in women aged 20–24 years in England a cause for concern?. Preventive Medicine, 2018, 107, 21-28.	3.4	26
66	Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. Lancet Public Health, The, 2018, 3, e34-e43.	10.0	41
67	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. Preventive Medicine, 2018, 111, 429-435.	3.4	15
68	What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. International Journal of Cancer, 2018, 142, 709-718.	5.1	45
69	Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux. BMC Cancer, 2018, 18, 784.	2.6	37
70	When should the errors in the UK's breast screening programme have been spotted?. Lancet, The, 2018, 391, 2319-2320.	13.7	0
71	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study. Scientific Reports, 2018, 8, 8374.	3.3	24
72	Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance. MSphere, 2018, 3, .	2.9	8

#	Article	IF	CITATIONS
73	The acceptability of high resolution anoscopy examination in patients attending a tertiary referral centre. BMC Cancer, 2018, 18, 554.	2.6	12
74	By how much could screening by primary human papillomavirus testing reduce cervical cancer incidence in England?. Journal of Medical Screening, 2017, 24, 110-112.	2.3	16
75	Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. The Lancet Gastroenterology and Hepatology, 2017, 2, 23-31.	8.1	87
76	Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study. BMJ Open, 2017, 7, e013901.	1.9	32
77	Medicine is the ultimate personalised technology. BMJ: British Medical Journal, 2017, 357, j1750.	2.3	0
78	Cancer risks in Nairobi (2000–2014) by ethnic group. International Journal of Cancer, 2017, 140, 788-797.	5.1	14
79	Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies?. Circulation, 2017, 135, 1985-1987.	1.6	23
80	Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ: British Medical Journal, 2017, 356, j1388.	2.3	20
81	Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. Evidence-Based Medicine, 2017, 22, 76-76.	0.6	2
82	Estimating efficacy in trials with selective crossover. Statistics in Medicine, 2017, 36, 2333-2346.	1.6	3
83	Factors related to interâ€observer reproducibility of conventional Pap smear cytology: a multilevel analysis of smear and laboratory characteristics. Cytopathology, 2017, 28, 192-202.	0.7	10
84	Colorectal adenomas, surveillance, and cancer – Authors' reply. Lancet Oncology, The, 2017, 18, e428.	10.7	1
85	Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Obstetrical and Gynecological Survey, 2017, 72, 280-282.	0.4	2
86	Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology, 2017, 3, 635-657.	0.5	121
87	Offering self-sampling to cervical screening non-attenders in primary care. Journal of Medical Screening, 2017, 24, 43-49.	2.3	22
88	On Standardized Relative Survival. Biometrics, 2017, 73, 473-482.	1.4	18
89	Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. Histopathology, 2017, 70, 203-210.	2.9	45
90	Systematic Review and Meta-Analysis of Individual Patient Data to Assess the Sensitivity of Cervical Cytology for Diagnosis of Cervical Cancer in Low- and Middle-Income Countries. Journal of Global Oncology, 2017, 3, 524-538.	0.5	5

#	Article	IF	CITATIONS
91	Cancer incidence in English children, adolescents and young people: past trends and projections to 2030. British Journal of Cancer, 2017, 117, 1865-1873.	6.4	11
92	Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. Oncotarget, 2017, 8, 50510-50520.	1.8	22
93	Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 479-487.	2.5	10
94	The age of cervical screening should be reduced. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 454-454.	2.3	1
95	Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review. British Journal of General Practice, 2016, 66, e871-e879.	1.4	9
96	Impact of Screening on Breast Cancer Mortality—Response. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 873-873.	2.5	0
97	Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 455-462.	2.5	79
98	Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?. International Journal of Cancer, 2016, 139, 1040-1045.	5.1	86
99	Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study. British Journal of Cancer, 2016, 115, 1140-1146.	6.4	253
100	Performance characteristics of visualising the cervix in symptomatic young females: a review of primary care records in females with and without cervical cancer. British Journal of General Practice, 2016, 66, e189-e192.	1.4	6
101	Ovarian cancer screening: UKCTOCS trial. Lancet, The, 2016, 387, 2602.	13.7	8
102	Black–white differences in cancer risk in <scp>H</scp> arare, <scp>Z</scp> imbabwe, during 1991–2010. International Journal of Cancer, 2016, 138, 1416-1421.	5.1	12
103	Time to diagnosis of Type I or <scp>II</scp> invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1012-1020.	2.3	21
104	Risk of preterm birth following surgical treatment for cervical disease: executive summary of a recent symposium. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1426-1429.	2.3	44
105	Analysis of trends is insufficient to posit the existence of two aetiological types of cervical cancer. BJOC: an International Journal of Obstetrics and Gynaecology, 2016, 123, 779-779.	2.3	0
106	Reply to the letter to the editor †Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis' by Louie et al Annals of Oncology, 2015, 26, 1031-1032.	1.2	1
107	Is the increased risk of preterm birth following excision for cervical intraepithelial neoplasia restricted to the first birth post treatment?. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 1191-1199.	2.3	24
108	Are rigid management protocols stifling innovation in cancer treatment?. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 1432-1434.	2.3	0

#	Article	IF	CITATIONS
109	MSLT â€k it's all about the lymph nodes…: reply from the authors. British Journal of Dermatology, 2015, 173, 627-628.	1.5	1
110	How many preterm births in England are due to excision of the cervical transformation zone? Nested case control study. BMC Pregnancy and Childbirth, 2015, 15, 232.	2.4	6
111	P235â€Prevalence and risk factors associated with oral HPV among sti clinic attendees. Sexually Transmitted Infections, 2015, 91, A93.2-A93.	1.9	0
112	Visual Inspection after Acetic Acid (VIA) Is Highly Heterogeneous in Primary Cervical Screening in Amazonian Peru. PLoS ONE, 2015, 10, e0115355.	2.5	19
113	Consultation rates in cervical screening non-attenders: opportunities to increase screening uptake in GP primary care. Journal of Medical Screening, 2015, 22, 93-99.	2.3	10
114	Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 817-824.	2.5	25
115	Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. Journal of Clinical Microbiology, 2015, 53, 2509-2516.	3.9	73
116	Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case–Control Study. PLoS Medicine, 2015, 12, e1001780.	8.4	212
117	A prospective doubleâ€blind crossâ€sectional study of the accuracy of the use of dry vaginal tampons for selfâ€sampling of human papillomaviruses. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 388-394.	2.3	5
118	Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Annals of Oncology, 2015, 26, 848-864.	1.2	153
119	Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncology, 2015, 51, 341-348.	1.5	83
120	Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice. British Journal of Dermatology, 2015, 172, 552-554.	1.5	14
121	Cervical cytology and the diagnosis of cervical cancer in older women. Journal of Medical Screening, 2015, 22, 207-212.	2.3	10
122	Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. British Journal of Cancer, 2014, 110, 1841-1846.	6.4	38
123	Response to comment on â€~Characteristics and screening history of women diagnosed with cervical cancer aged 20–29'. British Journal of Cancer, 2014, 111, 2374-2374.	6.4	0
124	Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. PLoS Medicine, 2014, 11, e1001585.	8.4	104
125	Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study. BMJ, The, 2014, 349, g6223-g6223.	6.0	86
126	The difference in sensitivity between HPV testing and cytology for detecting current and future CIN2+ increases over time. Evidence-Based Medicine, 2014, 19, 184-184.	0.6	1

#	Article	IF	CITATIONS
127	An ongoing case–control study to evaluate the NHS Bowel Cancer Screening Programme. BMC Cancer, 2014, 14, 945.	2.6	1
128	Estimating the workload associated with symptoms-based ovarian cancer screening in primary care: an audit of electronic medical records. BMC Family Practice, 2014, 15, 200.	2.9	4
129	A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. International Journal of Cancer, 2014, 134, 939-947.	5.1	22
130	Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study. British Journal of General Practice, 2014, 64, e602-e610.	1.4	50
131	HPV16 L1 and L2 DNA methylation predicts highâ€grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. International Journal of Cancer, 2013, 133, 637-644.	5.1	56
132	An ongoing case-control study to evaluate the NHS breast screening programme. BMC Cancer, 2013, 13, 596.	2.6	7
133	Characteristics of HPV infection over time in European women who are HIVâ€1 positive. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 41-49.	2.3	26
134	A Surveillance Model for Skin Cancer in Organ Transplant Recipients: A 22-Year Prospective Study in an Ethnically Diverse Population. American Journal of Transplantation, 2013, 13, 119-129.	4.7	122
135	Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. Journal of Pathology, 2013, 230, 107-117.	4.5	116
136	Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia in a Single NHS Hospital. International Journal of Gynecological Cancer, 2013, 23, 710-715.	2.5	6
137	New Strategies for Human Papillomavirus-Based Cervical Screening. Women's Health, 2013, 9, 443-452.	1.5	26
138	How much could primary human papillomavirus testing reduce cervical cancer incidence and morbidity?. Journal of Medical Screening, 2013, 20, 99-103.	2.3	17
139	Characteristics and screening history of women diagnosed with cervical cancer aged 20–29 years. British Journal of Cancer, 2013, 109, 35-41.	6.4	42
140	Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20–24. Journal of Medical Screening, 2012, 19, 127-132.	2.3	12
141	Screening mammography and socioeconomic inequalities in breast cancer survival. Annals of Oncology, 2012, 23, 285-286.	1.2	2
142	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. Journal of the National Cancer Institute, 2012, 104, 114-124.	6.3	49
143	Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ: British Medical Journal, 2012, 344, e670-e670.	2.3	79
144	Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. British Journal of Cancer, 2012, 106, 45-52.	6.4	23

#	Article	IF	CITATIONS
145	Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. British Journal of Cancer, 2012, 106, 1753-1759.	6.4	38
146	Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing. British Journal of Cancer, 2012, 107, 243-254.	6.4	42
147	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nature Genetics, 2012, 44, 1131-1136.	21.4	162
148	The impact of Jade Goody's diagnosis and death on the NHS Cervical Screening Programme. Journal of Medical Screening, 2012, 19, 89-93.	2.3	53
149	Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. BMJ, The, 2012, 345, e5174-e5174.	6.0	103
150	Age–Period–Cohort Models in Stata. The Stata Journal, 2012, 12, 45-60.	2.2	27
151	Review of cytology and histopathology as part of the NHS Cervical Screening Programme audit of invasive cervical cancers. Cytopathology, 2012, 23, 13-22.	0.7	21
152	Assessing Peanut Consumption in a Population of Mothers and Their Children in the UK. World Allergy Organization Journal, 2011, 4, 38-44.	3.5	9
153	Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 617-629.	2.8	16
154	Eurogin 2010 roadmap on cervical cancer prevention. International Journal of Cancer, 2011, 128, 2765-2774.	5.1	75
155	Safe thresholds for hybrid capture 2 test in primary cervical screening. BMJ: British Medical Journal, 2011, 342, d2941-d2941.	2.3	2
156	Cancer incidence in the United Kingdom: projections to the year 2030. British Journal of Cancer, 2011, 105, 1795-1803.	6.4	237
157	Evaluation of the nationwide cervical screening programme in Thailand: a case-control study. Journal of Medical Screening, 2011, 18, 147-153.	2.3	9
158	Single negative colposcopy: is it enough to rule out high-grade disease?. Journal of Medical Screening, 2011, 18, 160-161.	2.3	4
159	Risk Factors for High-Risk Human Papillomavirus Infection and Cofactors for High-Grade Cervical Disease in Peru. International Journal of Gynecological Cancer, 2011, 21, 1654-1663.	2.5	21
160	13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. British Journal of Cancer, 2011, 105, S66-S69.	6.4	162
161	In defence of lifetime risk. BMJ: British Medical Journal, 2011, 342, d1490.	2.3	1
162	Response to: Why young women should be screened for cervical cancer: The distinction between CIN2 and CIN3. International Journal of Cancer, 2010, 126, 2257-2258.	5.1	4

#	Article	IF	CITATIONS
163	Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). International Journal of Cancer, 2010, 127, 2639-2644.	5.1	27
164	Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20a€"29 in the UK. British Journal of Cancer, 2010, 102, 933-939.	6.4	79
165	Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. British Journal of Cancer, 2010, 102, 1405-1410.	6.4	47
166	Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. British Journal of Cancer, 2010, 102, 1608-1617.	6.4	51
167	ACOG Guidelines on Cervical Screening: A Step in the Right Direction. Journal of Medical Screening, 2010, 17, 55-56.	2.3	1
168	Has Cytology Become Obsolete as a Primary Test in Screening for Cervical Cancer?. Journal of Medical Screening, 2010, 17, 2-3.	2.3	2
169	Modelling the likely effect of the increase of the upper age limit from 70 to 73 for breast screening in the UK National Programme. Statistical Methods in Medical Research, 2010, 19, 547-555.	1.5	3
170	What is the Right Age for Cervical Cancer Screening?. Women's Health, 2010, 6, 1-4.	1.5	12
171	Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. International Journal of Epidemiology, 2009, 38, 814-830.	1.9	219
172	A deterministic model for estimating the reduction in colorectal cancer incidence due to endoscopic surveillance. Statistical Methods in Medical Research, 2009, 18, 163-182.	1.5	9
173	Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ: British Medical Journal, 2009, 339, b2968-b2968.	2.3	313
174	Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). European Urology, 2009, 56, 584-591.	1.9	180
175	A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. International Journal of Cancer, 2009, 124, 420-428.	5.1	84
176	How many cervical cancers are prevented by treatment of screenâ€detected disease in young women?. International Journal of Cancer, 2009, 124, 461-464.	5.1	38
177	Screening and adenocarcinoma of the cervix. International Journal of Cancer, 2009, 125, 525-529.	5.1	99
178	Household peanut consumption as a risk factor for the development of peanut allergy. Journal of Allergy and Clinical Immunology, 2009, 123, 417-423.	2.9	319
179	Further analysis of the ARTISTIC trial. Lancet Oncology, The, 2009, 10, 841-842.	10.7	20
180	The potential for prevention of colorectal cancer in the UK. European Journal of Cancer Prevention, 2009, 18, 179-190.	1.3	38

#	Article	IF	CITATIONS
181	Assessing participation of women in a cervical cancer screening program in Peru. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2009, 25, 189-95.	1.1	11
182	A retrospective survival analysis of whole brain radiotherapy (WBRT) for brain metastases at Mount Vernon Cancer Centre (MVCC). Journal of Clinical Oncology, 2009, 27, 2068-2068.	1.6	0
183	Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Familial Cancer, 2008, 7, 163-172.	1.9	123
184	Longâ€ŧerm followâ€up of cervical abnormalities among women screened by HPV testing and cytology—Results from the Hammersmith study. International Journal of Cancer, 2008, 122, 2294-2300.	5.1	70
185	Cancer mortality in the United Kingdom: projections to the year 2025. British Journal of Cancer, 2008, 99, 1549-1554.	6.4	63
186	Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. Journal of Allergy and Clinical Immunology, 2008, 122, 984-991.	2.9	726
187	Predicting the impact of the screening programme for colorectal cancer in the UK. Journal of Medical Screening, 2008, 15, 163-174.	2.3	39
188	Replication Timing Profile Reflects the Distinct Functional and Genomic Features of the MHC Class II Region. Cell Cycle, 2007, 6, 2393-2398.	2.6	6
189	Phenocopies in families seen by cancer geneticists. Journal of Medical Genetics, 2007, 44, e82-e82.	3.2	2
190	Cervical cancer prevention and hormonal contraception. Lancet, The, 2007, 370, 1591-1592.	13.7	18
191	Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. International Journal of Cancer, 2007, 121, 796-802.	5.1	99
192	Colposcopy is not necessary to assess the risk to the cervix in HIVâ€positive women: An international cohort study of cervical pathology in HIVâ€1 positive women. International Journal of Cancer, 2007, 121, 2484-2491.	5.1	37
193	Estimating the Effect of Treatment in a Proportional Hazards Model in the Presence of Non-Compliance and Contamination. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2007, 69, 565-588.	2.2	42
194	Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?. Journal of Clinical Oncology, 2007, 25, 541-541.	1.6	2
195	Liquid-based versus conventional cervical cytology. Lancet, The, 2006, 367, 1481.	13.7	5
196	Prospective Results of Surveillance Colonoscopy in Dominant Familial Colorectal Cancer With and Without Lynch Syndrome. Gastroenterology, 2006, 130, 1995-2000.	1.3	72
197	Call and recall cervical screening programme: Screening interval and age limits. Current Diagnostic Pathology, 2006, 12, 114-126.	0.4	11
198	Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine, 2006, 24, S78-S89.	3.8	393

#	Article	IF	CITATIONS
199	A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene, 2006, 25, 6544-6553.	5.9	64
200	Chemoprevention of cervical cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 295-305.	2.8	7
201	Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. International Journal of Cancer, 2006, 118, 2048-2055.	5.1	186
202	Methodological issues in international comparison of interval breast cancers. International Journal of Cancer, 2006, 119, 1158-1163.	5.1	48
203	Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer, 2006, 119, 1095-1101.	5.1	922
204	Cervical screening in 20–24-year olds. Journal of Medical Screening, 2006, 13, 62-63.	2.3	5
205	Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 714-719.	7.1	269
206	Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. British Journal of Cancer, 2006, 94, 460-464.	6.4	65
207	Two-year recall of maternal peanut consumption using a food-frequency questionnaire. South African Journal of Clinical Nutrition, 2006, 19, 154-160.	0.7	3
208	Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ: British Medical Journal, 2005, 331, 1047.	2.3	174
209	A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. European Journal of Cancer, 2005, 41, 2141-2149.	2.8	107
210	Refining the Amsterdam Criteria and Bethesda Guidelines: Testing Algorithms for the Prediction of Mismatch Repair Mutation Status in the Familial Cancer Clinic. Journal of Clinical Oncology, 2004, 22, 4934-4943.	1.6	101
211	Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case–control study in Florence. British Journal of Cancer, 2004, 90, 1784-1786.	6.4	87
212	Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. British Journal of Dermatology, 2004, 150, 949-957.	1.5	153
213	Reply: The value of case—control audits of screening. British Journal of Cancer, 2004, 90, 1109-1110.	6.4	1
214	Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case–control study. European Journal of Cancer, 2004, 40, 429-435.	2.8	99
215	Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions. Journal of Cell Biology, 2004, 164, 515-526.	5.2	206
216	Cervical screening in adolescents—at least do no harm. Lancet, The, 2004, 364, 1642-1644.	13.7	21

#	Article	IF	CITATIONS
217	Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. British Journal of Cancer, 2003, 89, 88-93.	6.4	296
218	Iterated residuals and time-varying covariate effects in Cox regression. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2003, 65, 473-488.	2.2	16
219	The UK breast-screening programme should start at age 47 years. Lancet, The, 2003, 362, 246-247.	13.7	5
220	Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, The, 2003, 362, 1871-1876.	13.7	467
221	Evaluation of the UK breast screening programmes. Annals of Oncology, 2003, 14, 1206-1208.	1.2	24
222	X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3311-3314.	7.1	121
223	Outcomes of screening to prevent cancer: Think of screening as insurance. BMJ: British Medical Journal, 2003, 327, 50-50.	2.3	8
224	On the Expected Number of Cancer Deaths During Follow-Up of an Initially Cancer-Free Cohort. Epidemiology, 2003, 14, 108-110.	2.7	12
225	Adjusted Nelson–Aalen Estimates With Retrospective Matching. Journal of the American Statistical Association, 2002, 97, 245-256.	3.1	14
226	Could HPV testing become the sole primary cervical screening test?. Journal of Medical Screening, 2002, 9, 49-51.	2.3	41
227	Cancer screening for medical oncologists: importance of quality control and audit. Annals of Oncology, 2002, 13, 199-204.	1.2	3
228	How Many Mutations in a Cancer?. American Journal of Pathology, 2002, 160, 755-758.	3.8	110
229	The Influence of Genetics and Environmental Factors in the Pathogenesis of Acne: A Twin Study of Acne in Women. Journal of Investigative Dermatology, 2002, 119, 1317-1322.	0.7	161
230	A weighted Kaplan-Meier estimator for matched data with application to the comparison of chemotherapy and bone-marrow transplant in leukaemia. Statistics in Medicine, 2002, 21, 3847-3864.	1.6	32
231	Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet, The, 2001, 357, 1490-1493.	13.7	156
232	Natural history of cervical human papillomavirus. Lancet, The, 2001, 358, 1550-1551.	13.7	6
233	Routine audit is an ethical requirement of screening. BMJ: British Medical Journal, 2001, 322, 1179-1179.	2.3	19
234	Estimating prevalence when the true disease status is incompletely ascertained. Statistics in Medicine, 2001, 20, 935-949.	1.6	13

14

#	Article	IF	CITATIONS
235	Miscellanea. A note on scaled Schoenfeld residuals for the proportional hazards model. Biometrika, 2001, 88, 565-571.	2.4	20
236	PML bodies associate specifically with the MHC gene cluster in interphase nuclei. Journal of Cell Science, 2001, 114, 3705-3716.	2.0	109
237	Routine audit is an ethical requirement of screening. BMJ: British Medical Journal, 2001, 322, 1179.	2.3	6
238	PML bodies associate specifically with the MHC gene cluster in interphase nuclei. Journal of Cell Science, 2001, 114, 3705-16.	2.0	88
239	Analysis of cervical cancer mortality and incidence data from England and Wales: evidence of a beneficial effect of screening. Journal of the Royal Statistical Society Series A: Statistics in Society, 2000, 163, 191-209.	1.1	26
240	A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. British Journal of Cancer, 2000, 83, 561-565.	6.4	131
241	Genetics of Risk Factors for Melanoma: an Adult Twin Study of Nevi and Freckles. Journal of the National Cancer Institute, 2000, 92, 457-463.	6.3	127
242	Photoadaptation to ultraviolet (UV) radiation in vivo: photoproducts in epidermal cells following UVB therapy for psoriasis. British Journal of Dermatology, 2000, 143, 477-483.	1.5	2
243	Standardized Lifetime Risk. American Journal of Epidemiology, 1999, 149, 869-875.	3.4	50
244	Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ: British Medical Journal, 1999, 318, 1244-1245.	2.3	150
245	Melanoma yield, number of biopsies and missed melanomas in a British teaching hospital pigmented lesion clinic: a 9-year retrospective study. British Journal of Dermatology, 1999, 140, 243-248.	1.5	25
246	The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. British Journal of Cancer, 1998, 77, 505-510.	6.4	107
247	Solar keratoses: A risk factor for melanoma but negative association with melanocytic naevi. , 1998, 78, 8-12.		71
248	APC in the regulation of intestinal crypt fission. Journal of Pathology, 1998, 185, 246-255.	4.5	147
249	Supersites within superfolds. Binding site similarity in the absence of homology 1 1Edited by J. Thornton. Journal of Molecular Biology, 1998, 282, 903-918.	4.2	221
250	From Genotypes to Genes: Doubling the Sample Size. Biometrics, 1997, 53, 1253.	1.4	775
251	Risk factors for invasive cervix cancer in young women. European Journal of Cancer, 1996, 32, 836-841.	2.8	49
252	Effect of smoking cessation on cervical lesion size. Lancet, The, 1996, 347, 941-943.	13.7	113

#	Article	IF	CITATIONS
253	Efficiently Weighted Estimating Equations with Application to Proportional Excess Hazards. , 1996, , 281-289.		0
254	Dotplots. Journal of the Royal Statistical Society Series C: Applied Statistics, 1996, 45, 219.	1.0	9
255	Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. British Journal of Cancer, 1996, 73, 1605-1611.	6.4	228
256	EVALUATION OF LONG-TERM SURVIVAL: USE OF DIAGNOSTICS AND ROBUST ESTIMATORS WITH COX'S PROPORTIONAL HAZARDS MODEL. , 1996, 15, 2763-2780.		31
257	Proportional excess hazards. Biometrika, 1996, 83, 127-141.	2.4	57
258	EVALUATION OF LONGâ€TERM SURVIVAL: USE OF DIAGNOSTICS AND ROBUST ESTIMATORS WITH COX'S PROPORTIONAL HAZARDS MODEL. Statistics in Medicine, 1996, 15, 2763-2780.	1.6	1
259	Full description of controls is needed in study. BMJ: British Medical Journal, 1996, 312, 577-577.	2.3	1
260	Cervical sampling devices. BMJ: British Medical Journal, 1996, 313, 1275-1276.	2.3	8
261	Risk of ocular melanoma in relation to cutaneous and IRIS naevi. International Journal of Cancer, 1995, 60, 622-626.	5.1	58
262	Efficiently weighted estimating equations with application to proportional excess hazards. Lifetime Data Analysis, 1995, 1, 49-57.	0.9	7
263	Cervical screening: what is the point?. Lancet, The, 1995, 346, 244-247.	13.7	2
264	Accelerated decline in cervical cancer mortality in England and Wales. Lancet, The, 1995, 346, 1566-1567.	13.7	95
265	Non-Hodgkin's lymphoma and skin cancer. BMJ: British Medical Journal, 1995, 311, 749-749.	2.3	9
266	A partly parametric additive risk model. Biometrika, 1994, 81, 501-514.	2.4	218
267	Endometriosis during tamoxifen treatment. Lancet, The, 1994, 343, 978.	13.7	10
268	Small-Sample Study of an Efficient Estimator of the Odds Ratio under Multiple Matching. Biometrics, 1994, 50, 140.	1.4	3
269	Maximum Weighted Partial Likelihood Estimators for the Cox Model. Journal of the American Statistical Association, 1993, 88, 144.	3.1	13
270	How common is the atypical mole syndrome phenotype in apparently sporadic melanoma?. Journal of the American Academy of Dermatology, 1993, 29, 989-996.	1.2	88

#	Article	IF	CITATIONS
271	Maximum Weighted Partial Likelihood Estimators for the Cox Model. Journal of the American Statistical Association, 1993, 88, 144-152.	3.1	41
272	Some New Estimators for Cox Regression. Annals of Statistics, 1993, 21, 1721.	2.6	40
273	Ingested Arsenic, Keratoses, and Bladder Cancer. American Journal of Epidemiology, 1992, 136, 417-421.	3.4	130
274	A note on the presentation of matched case-control data. Statistics in Medicine, 1992, 11, 617-620.	1.6	12
275	Information Bounds For the Additive and Multiplicative Intensity Models. , 1992, , 249-265.		9
276	Trends in cervical cancer mortality. Lancet, The, 1991, 338, 818-819.	13.7	17
277	Correspondence Effect of Introducing A Restrictive Cervical Screening Policy On the Detection of Cervical Cancer. Cytopathology, 1991, 2, 277-278.	0.7	0
278	Cervical Screening. , 0, , 118-132.		0
279	Prospective observational study: cervical cancer smears. BMJ, The, 0, , b2971.	6.0	0